Trial
NCT05820763
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Karyopharm Therapeutics Inc
Condition
Multiple Myeloma
Intervention
Selinexor
Why stopped
Study sponsor decided to close study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-10